The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a ...

SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent ...

Thus, oncology providers need a comprehensive resource regarding effective PDAC UGT integration into clinical practice. Therefore, we applied a narrative review approach to summarize 17 publications ...

At booth #25031, Myriad Oncology will unveil a new brand identity underscoring its streamlined approach to delivering germline testing, tumor profiling and companion diagnostic testing – enabling ...

The genetic testing market is set to reach USD 49.72 billion by 2033, expanding at a CAGR of 9.79% from USD 23.55 billion in ...

Fulgent Genetics reported its 2025 results in the past, with revenue rising to US$322.67 million while the net loss widened to US$60.51 million, and it issued 2026 guidance calling for about US$350.00 ...

A 46-year-old man was diagnosed with pleural effusion - a case of fluid accumulation around the lungs. According to his diagnostic tests, he was a confirmed case of stage 4 adenocarcinoma of the lung ...

BOSTON and ROLLE, Switzerland, Sept. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a ...

Solid tumors, prevalent across various systems such as the respiratory, digestive, urinary, and gynecologic systems, constitute a significant challenge in adult oncology. These tumors are ...

Genetic predisposition to excess body weight was linked to 15% higher mortality in breast cancer survivors, with more walking needed to offset risk.